<DOC>
	<DOC>NCT03017404</DOC>
	<brief_summary>To study the maximum tolerated dose of Doxorubicin Hydrochloride Liposome Injection combination with cyclophosphamide and sequential treatment of docetaxel for patients with locally advanced breast cancer</brief_summary>
	<brief_title>A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Female patients newly diagnosed breast cancer≥18 and ≤70 years of age; Karnofsky performance status≥70 and measurable or evaluable; Stages ⅢaⅢC; Baseline left ventricular ejection fraction (LVEF) ≥ 50%; Adequate marrow function (WBC count＞ 4.0×10(9)/L, neutrophil＞ 2.0×10(9)/L, platelet count ＞ 100×10(9)/L，hemoglobin ＞ 90g/L ); AST and ALT ≤1.5× institutional upper limit of normal, alkaline phosphatase ≤2.5×institutional upper limit of normal，bilirubin ≤institutional upper limit of normal; Serum creatinine ≥ 44µmol/L and ≤ 133 µmol/L; Expected lifetime ≥ 12 months; Pregnancy tests of reproductive age women is negative; All patients provided written informed consent. Distant metastasis; Severe heart failure (NYHA grade II or higher); Active and uncontrolled severe infection; Hypersensitivity to anthracycline therapy or a history of severe hypersensitivity reactions to products containing liposomal doxorubicin and docetaxel; Have accepted any other antitumor drug within 30 days before the first dose of doxorubicin hydrochloride liposome or doxorubicin; Pregnancy or breast feeding; Other situations that investigators consider as contraindication for this study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>